09.10.13
The Spanish biotech company AB-Biotics has been granted a patent by the European Patent Office (EPO), which protects the composition of its cholesterol-lowering probiotic, AB-Life.
Filed on September 28, 2010, the patent (EP2485743) protects compositions comprised of the probiotic strains of Lactobacillus plantarum CECT 757, CECT 7528 and CECT 7529. The patent also protects the administration of AB-Life with other cholesterol-lowering products such as statins.
AB-Life probiotic strains have been found useful for the prevention and/or the treatment of hypercholesterolemia and cardiovascular disorders. AB-Life strains are suitable for pharmaceutical, veterinary and edible compositions.
Filed on September 28, 2010, the patent (EP2485743) protects compositions comprised of the probiotic strains of Lactobacillus plantarum CECT 757, CECT 7528 and CECT 7529. The patent also protects the administration of AB-Life with other cholesterol-lowering products such as statins.
AB-Life probiotic strains have been found useful for the prevention and/or the treatment of hypercholesterolemia and cardiovascular disorders. AB-Life strains are suitable for pharmaceutical, veterinary and edible compositions.
